Trusted Resources: Evidence & Education
Scientific literature and patient education texts
How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease
source: British Journal of Haematology
year: 2015
authors: Gardner K, Hoppe C, Mijovic A, Thein SL
summary/abstract:Transfusion therapy is effective in the prevention and treatment of many complications of sickle cell disease (SCD). However, its benefits must be balanced against its risks, including delayed haemolytic transfusion reactions (DHTR). Not only is the relative rate of alloimmunization higher in patients with SCD than in other patient populations, but attendant risks associated with DHTR are even greater in SCD. Clinicians’ awareness of DHTR events is poor because symptoms of DHTR mimic acute vaso-occlusive pain and immunohaematology findings are often negative. Transfusions delivered in the acute rather than elective setting appear to confer a higher risk of DHTR. Management of DHTR in SCD depends on the clinical severity, ranging from supportive care to immunosuppression, and optimization of erythropoiesis. DHTR must be considered in any recently transfused patient presenting with acute sickle cell pain. Meticulous documentation of transfusion and immunohaematology history is key. We anticipate an increase in DHTR events in SCD patients with the increasing use of red blood cell transfusion therapy.
organization: King's College London; King's College Hospital NHS Foundation Trust, London; Children's Hospital and Research Center Oakland; National Institutes of Health/National Heart Lung and Blood Institute, Bethesda, USADOI: 10.1111/bjh.13494
read more full text
Related Content
-
Greater Number of Perceived Barriers to Hydroxyurea Associated With Poorer Health-Related Quality of Life in Youth W...Background: Despite medical benefits, ...
-
Bioverativ and Sangamo announce FDA acceptance of IND application for gene-edited cell therapy BIVV003 to treat sick...Bioverativ Inc., a Sanofi company dedi...
-
Sickle Cell Disease: Current Treatment and Emerging TherapiesSickle cell disease (SCD) is among the m...
-
Diabetes Drug, Metformin, Suggested as ‘Breakthrough’ Treatment for Sickle Cell AnemiaMetformin, a common drug for Type 2 diab...
-
Sickle Cell Disease: Gene-Editing Tools Point to Possible Ultimate CureRecent advances in CRISPR/Cas9 gene-edit...
-
Sickle cell cure is real, as this Kansas patient provesIntense pain. Fatigue. Repeated infectio...
-
Spectra Optia Device Save Way to Treat Sickle Cell While Using Less Blood Cell Packs, Study FindsThe blood-separation device Spectra Opti...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.